Protein Kinase Selectivity Profiling Using Microfluid Mobility Shift Assays.
Biochemical selectivity profiling is an integral part of early drug development. Typically compounds from optimization phase are regularly tested for off-target activities within or across target families. This article presents workflow and critical aspects of biochemical protein kinase profiling based on microfluidic mobility shift assays.
CPC Screening Sciences, Novartis Pharma AG, Novartis Institutes for Biomedical Research, 4002, Basel, Switzerland. peter.drueckes@novartis.com.
Peter
P
Drueckes
D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000295:instrumentation / Q000379:methods*; D024202:Electrophoretic Mobility Shift Assay / Q000295:instrumentation / Q000379:methods*; D004867:Equipment Design; D006801:Humans; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000378:metabolism*
D047428:Protein Kinase Inhibitors; D011494:Protein Kinases
Compound preparation; Kinase; Microfluidic mobility shift assay; Selectivity profiling